



## EuroSIDA Newsletter

April 2024

### **Dear EuroSIDA Study Investigators,**

As we embrace the season of spring in 2024, the EuroSIDA Coordinating Centre extends warm wishes to our international partners. Your consistent dedication to the study remains highly valued. We are delighted to share with you the latest key updates from the EuroSIDA study.

### **Study Updates**

#### **Dataset 51 (DS51)**

We are pleased to announce that Dataset 51 was successfully closed on 1st January 2024 for REST and REDCap sites. We received 9,600 completed forms in REDCap and REST data from 2,200 active participants. In total, we have received data from approximately 11,800 participants.

Currently, we are in the process of cleaning and downloading Dataset 51 to the EuroSIDA database.

#### **Cabotegravir**

Data collection for injectable long-acting cabotegravir and rilpivirine treatment is ongoing through two separate REDCap projects. We kindly remind all sites to ensure updates of all injection dates. To date, we have received data on 161 treatments. We encourage sites to complete the form once annually during data collection (between October – December).

#### **MISTRAL**

The MISTRAL study continues to progress positively. We are pleased to report that 21 EuroSIDA sites across 11 countries are open, with **800 participants** enrolled in the study.

Of these participants, 506 are new MISTRAL participants, while 294 are existing EuroSIDA participants. Our goal for 2024 is to **reach the target of 1,000 enrolments**. The aim is that participants have 2 study visits providing fecal and blood samples and at least 2 years of follow-up. Nearly 8,000 samples (stool, plasma, and whole blood) have been received at CHIP and transferred to IrsiCaixa in Spain. The analyses of enrolment samples of the first 500 participants will begin shortly.

So far, 10 virtual training sessions have been held. If you are part of MISTRAL and would like to participate in a training session, you can send an e-mail to the [MISTRAL Secretariat](#).

For more information on the MISTRAL study [click here](#).

## Potential Biomarker Studies - clinical events with stored plasma

We are excited to present a summary of clinical events and prior blood samples available in EuroSIDA, updated as of January 2024. This overview provides insights into various events including those with any prior sample or sample within 12 months prior to the event. We encourage all EuroSIDA sites to explore new **project proposals** based on these clinical events with stored plasma. Please reach out to the [Coordinating Centre](#) with any suggestions or inquiries.

	Events		With any prior sample		With sample within 12 months prior to event	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
<b>Death</b>	3074	14.3%	1885	61.3%	727	23.6%
<b>CVD</b>	1195	5.6%	848	71.0%	425	35.6%
<b>ESLD</b>	424	2.0%	220	51.9%	107	25.2%
<b>ESRD</b>	143	0.7%	103	72.0%	49	34.3%
<b>NADM</b>	1371	6.4%	926	67.5%	418	30.5%
Anal	248	1.2%	170	68.5%	75	30.2%
Bladder	64	0.3%	48	75.0%	20	31.3%
Breast	73	0.3%	50	68.5%	17	23.3%
Colon	59	0.3%	33	55.9%	10	16.9%
Head and neck	59	0.3%	34	57.6%	11	18.6%
Liver	141	0.7%	80	56.7%	31	22.0%
Lung	198	0.9%	131	66.2%	64	32.3%
Malignant melanoma	59	0.3%	47	79.7%	18	30.5%
Prostate	138	0.6%	97	70.3%	38	27.5%

*Updated as of January 2024. All numbers are estimates and exact events/ samples would depend on inclusion and exclusion criteria and study design. *n* should be considered maximum. Individual NADM are displayed if *n*>50.*

## Reminders

We want to remind you of some matters that require your attention:

## Data Processing Agreement (DPA)

We are in the process of collecting a DPA from all the sites that supply plasma samples to EuroSIDA. If your site has received a DPA template and is **supplying plasma samples**, kindly fill out and return the DPA.

## Regulatory Approvals

Sites have received reminders concerning the submission and approval status of regulatory documents. We are eagerly looking forward to advancing the process and ensuring that all necessary approvals are obtained within the required timeframes.

Therefore, we kindly urge you to **keep us informed of any updates** or progress from your respective ethics committees to facilitate the progress.

## Staff Changes

Remember to notify the [EuroSIDA Coordinating Centre](#) if there are any changes in staff or principal investigators within your team. If there is a change in staff, we will update REDCap access and adjust our study group and database accordingly.

## Reimbursement

The reimbursement process is scheduled to take place in June/July 2024 and the intention is that all sites will be compensated latest in September. To ensure compensation of the following forms this year, we kindly request all participating sites to complete Event, CoDe, and Cabotegravir forms in REDCap by **1<sup>st</sup> May 2024**. Event forms completed after 1<sup>st</sup> May 2024 will be reimbursed in 2025. All REDCap and REST forms submitted in dataset 51 with new data will be reimbursed.

## Query Form Access in REDCap

We are pleased to introduce you to a new REDCap project called 'Query Form', which is now available in your REDCap project list. The form has been created to consolidate all unresolved queries related to Event and CoDe forms, to centralize communication and to minimize extensive email correspondence between sites and coordinating staff. However, for minor queries, they will continue to be handled via email.

With that in mind, we kindly request that you inform us of anyone who **requires access** to the query form.

Working instruction for the query form can be found [here](#).

## EuroSIDA Steering Committee Election 2024-2028

We are happy to welcome **Justyna Kowalska** as the next chair of the EuroSIDA Steering Committee 2024-2028, who joins us from the Department of Adult's Infectious Diseases, Medical University of Warsaw in Poland. She brings many years of

experience as a EuroSIDA investigator and researcher. It is worth mentioning that Justyna was already a member of the committee. Justyna defended her PhD thesis based on EuroSIDA data in 2011. We welcome her and look forward to the collaboration.

We would also like to thank Gilles Wandeler for his contributions during his tenure as chair for the last five years. His dedication has been important to the committee and EuroSIDA, and we deeply appreciate his efforts.

## **EuroSIDA Investigator Meeting in Glasgow, November 2024**

We are excited to announce that we will host our traditional annual EuroSIDA investigator meeting again. Invitations will be sent out to all EuroSIDA investigators to participate in the meeting which will take place during the HIV Glasgow conference on November 10-13, 2024.

More information regarding the meetings will be announced as we approach.

## **Conference Recap**

### **19<sup>th</sup> European AIDS Conference (EACS), Warsaw, Poland, 18-21 October 2023**

A EuroSIDA investigator meeting was held during the EACS conference. The meeting was dedicated to update on EuroSIDA and MISTRAL studies and to discuss future research in EuroSIDA. More importantly, it was wonderful to greet all the investigators in person again. EuroSIDA was finely represented with 3 oral and 1 poster presentations at EACS, and one even won the EACS Rapid Abstract Award. They are listed below.

1. **Effect of ART, immunological-virological status and prior tuberculosis on mortality among people with HIV in Europe.** [Oral presentation](#) by Erich Tusch on behalf of the EuroSIDA Study Group.
2. **Temporal trends and impact of COVID-19 on the HIV cascade of care across Europe between 2016-2021.** [Oral presentation](#) by Lars Peters on behalf of the EuroSIDA Study Group.
3. **Disruptions in testing and treatment services for hepatitis C virus during the SARS-CoV-2 epidemic among individuals with HIV susceptible for HCV reinfection: results from the EuroSIDA study.** [Oral presentation](#) by Anders Boyd on behalf of the EuroSIDA Study Group. Winner of the EACS **Rapid Abstract Award!**

4. **Differences in integrated assessment and management of non-communicable diseases (NCDs) for people with HIV across the WHO European Region** by Christian Kraef on behalf of EuroSIDA Study Group. [Poster presentation](#).

## **Conference on Retrovirus and Opportunistic Infections (CROI 2024), Denver, Colorado, USA, 3-6 March**

1. **Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021.** [Poster presentation](#) by Nadine Jaschinski on behalf of the RESPOND study Group.
2. **Increased Cancer Risk with Low CD4 Counts Persists Despite Over 2 Years of Virological Suppression.** [Poster presentation](#) by Jennifer Hoy on behalf of the RESPOND Study Group.
3. **Novel Biomarkers as Determinants of HBsAg Loss in Persons with HIV/HBV on Tenofovir.** [Poster presentation](#) by Lorin Bgré on behalf of the EuroSIDA Study Group.

## **IWHOD 2024, Vilamoura, Portugal, 21-23 March 2024**

1. **Trends in AIDS-defining illnesses among people living with HIV in Europe: results from the EuroSIDA study (2003-2022)** presented by Wendy Bannister on behalf of the EuroSIDA Study Group.

## **Publications and Presentations**

### **EuroSIDA Reaches 339 Publications!**

The EuroSIDA study has reached 339 publications. Four manuscripts have been published since our last newsletter. Details of the latest publications are listed below:

### **Latest Publications**

1. **Differences in integrated assessment and management of non-communicable diseases (NCDs) for people with HIV across the WHO European Region.** Kraef C, Singh S, Fursa O, Abutidze A, Rukhadze N, Mulabdic V, Yancheva N, Mehmeti M, Balayan T, Harxhi A, Trajanovska J, Mackintosh C, Duvivier C, Beniowski M, Jilich D, Reikvam DH, Tau L, Podlekareva D, Ryom L, Peters L, Kowalska J, Kirk O; EuroSIDA Study Group. HIV Med. 2024. Epub ahead of print. [Abstract](#)
2. **SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.** Fursa O, Bannister W, Neesgaard B, Podlekareva D, Kowalska J, Benfield T, Gerstoft J, Reekie J, Rasmussen LD, Aho I, Guaraldi G, Staub T, Miro JM, Laporte JM, Elbirt D, Trofimova

## In Press

1. **Association between change in body mass index and risk of hypertension and dyslipidemia in people receiving integrase inhibitors and/or tenofovir alafenamide compared to other contemporary antiretroviral regimes:**

Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Pfistershammer KG, Wit F, De Wit S, Castagna A, Monforte AD, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Matharu LB, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos L. The RESPOND consortium of prospective cohorts. Published in Lancet HIV.

All EuroSIDA publications can be found [here](#).

## RESPOND Update

The collection of RESPOND Dataset 6 was successfully closed on 1<sup>st</sup> January 2024. EuroSIDA remains the largest contributor of participants in RESPOND.

RESPOND presentations can be found [here](#).

RESPOND publications can be found [here](#).

---

We wish everyone in the EuroSIDA study a wonderful spring and we look forward to continuing the great partnership we have with all of you!



You are receiving this email because you are affiliated with the EuroSIDA study. By providing your contact details to the EuroSIDA Coordinating Centre, you are included in the mailing list for the EuroSIDA study.

### Contact

Please always feel free to contact the EuroSIDA coordinating centre at [eurosidea.rigshospitalet@regionh.dk](mailto:eurosidea.rigshospitalet@regionh.dk).

No question is too small or too big, we are happy to assist in all matters!

### EuroSIDA Coordinating Centre.

Rigshospitalet  
CHIP, Section 2100  
Blegdamsvej 9  
DK-2100 Copenhagen Ø,  
Denmark

Web: [www.regionh.dk](http://www.regionh.dk) [www.chip.dk](http://www.chip.dk)